DGAP-Adhoc Biotest AG: Increase in Earnings after Tex for Fiscal Year 2012

    Nachrichtenquelle: EQS Group AG
     |  22.01.2013, 19:25  |  361 Aufrufe  |   | 

    Biotest AG  / Key word(s): Change in Forecast

    22.01.2013 19:25

    Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
    by DGAP - a company of EquityStory AG.
    The issuer is solely responsible for the content of this announcement.

    Ad-hoc RELEASE
    Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

    Dreieich, 22 January 2013. Biotest AG announces that earnings after tax for
    the year 2012 will increase by approx. EUR 10 million. (This additional
    income will be reported in earnings after tax from Discontinued Operation.)
    This income results from the sale of the former segment Microbiological
    Monitoring. At the time of the sale a patent law suit was still pending, in
    which heipha Dr. Müller GmbH was accused of infringing a patent of a
    plaintiff. The patent claim has now been effectively declared null and void
    by the Federal Court of Justice. Thereupon the plaintiff withdraw the
    lawsuit against heipha Dr. Müller GmbH. Biotest is entitled to claim the
    remaining purchase price from the buyer of the sold business.

    Biotest Aktiengesellschaft
    The Executive Management Board

    Biotest AG
    Landsteinerstr. 5
    D-63303 Dreieich


    This document contains forward-looking statements on overall economic
    development as well as on the business, earnings, financial and assets
    position of Biotest AG and its subsidiaries. These statements are based on
    current plans, estimates, forecasts and expectations of the company and are
    thus subject to risks and elements of uncertainty that could result in
    significant deviation of actual developments from expected developments.
    The forward-looking statements are only valid at the time of publication.
    Biotest does not intend to update the forward-looking statements and
    assumes no obligation to do so.

    About Biotest

    Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a
    value added chain that extends from pre-clinical and clinical development
    to worldwide sales, Biotest has specialised primarily in the areas of
    application of immunology and haematology. In its Plasma Protein portfolio,
    Biotest develops and markets immunoglobulins, coagulation factors and
    albumins based on human blood plasma. These are used for diseases of the
    immune and haematopoietic systems.  Biotest also researches into the
    clinical development of monoclonal antibodies, including in the indications
    of rheumatoid arthritis and cancer of plasma cells. Biotest has more than
    1,600 employees worldwide. The preference shares of Biotest AG are listed
    in the SDAX on the Frankfurt stock exchange.

    Securities´ ID No., ISIN ordinary shares: 522720, DE0005227201
    Securities´ ID No., ISIN preference shares: 522723, DE0005227235
    Listing: Prime Standard
    Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
    München, Stuttgart

    22.01.2013 DGAP´s Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    Language:     English
    Company:      Biotest AG
                  Landsteinerstraße 5
                  63303 Dreieich
    Phone:        0 61 03 - 8 01-0
    Fax:          0 61 03 - 8 01-150
    E-mail:       investor_relations@biotest.de
    Internet:     http://www.biotest.de
    ISIN:         DE0005227235, DE0005227201
    WKN:          522723, 522720
    Indices:      SDAX
    Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
                  in Berlin, Düsseldorf, Hamburg, Stuttgart

    End of Announcement                             DGAP News-Service

    Wertpapier: BiotestBiotest Vz

    Themen: AktienDAXISIN

    Schreibe Deinen Kommentar



    Enthaltene Werte

    WertpapierKursZeitPerf. %


    Weitere Nachrichten des Autors


    Top Nachrichten aus der Rubrik